Inactive

Extend Closing Date Effective 2/5/2024 This amendment is being issued to extend the closing date for solicitation 36E79724R0006 for Anti-CD20 Antibodies. The solicitation due date has been extended to... Extend Closing Date Effective 2/5/2024 This amendment is being issued to extend the closing date for solicitation 36E79724R0006 for Anti-CD20 Antibodies. The solicitation due date has been extended to February 20, 2024 and all offers are due by 2:30PM Central Time.

Inactive

The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79724R0006 for an unrestricted procurement for Anti-CD20 Antibodies for the Department of Veterans Affairs (VA), Burea... The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79724R0006 for an unrestricted procurement for Anti-CD20 Antibodies for the Department of Veterans Affairs (VA), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC or UPC number that is unique to the offeror. Solicitation #36E79724R0006 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about February 5, 2024, with a tentative closing date of February 19, 2024 . The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: https://sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Youlanda Duggar. Questions can be e-mailed to: Youlanda.Duggar@va.gov. The estimated annual requirements are as follows: ITEM DESCRIPTION DOSES/YEAR TOTAL FOR NEW PATIENTS 1A OCRELIZUMAB 300MG/10ML 6 1,290 OR 1B UBLITUXIMAB-XIIY 150MG/6ML 10 1,290 OR 1C OFATUMUMAB 20MG/0.4ML 14 1,290 PEN INJ (SENSOREADY)